Home
Resources
Publications
A Translational Systems Pharmacology Model for Aβ Kinetics in Mouse, Monkey, and Human

A Translational Systems Pharmacology Model for Aβ Kinetics in Mouse, Monkey, and Human

T Karelina, O Demin, T Nicholas, Y Lu, S Duvvuri, H A Barton

CPT Pharmacometrics Syst Pharmacol. 2017 Oct;6(10):666-675.

PMID: 28571112

Abstract:

A mechanistic model of amyloid beta production, degradation, and distribution was constructed for mouse, monkey, and human, calibrated and externally verified across multiple datasets. Simulations of single-dose avagacestat treatment demonstrate that the Aβ42 brain inhibition may exceed that in cerebrospinal fluid (CSF). The dose that achieves 50% CSF Aβ40 inhibition for humans (both healthy and with Alzheimer's disease (AD)) is about 1 mpk, one order of magnitude lower than for mouse (10 mpk), mainly because of differences in pharmacokinetics. The predicted maximal percent of brain Aβ42 inhibition after single-dose avagacestat is higher for AD subjects (about 60%) than for healthy individuals (about 45%). The probability of achieving a normal physiological level for Aβ42 in brain (1 nM) during multiple avagacestat dosing can be increased by using a dosing regimen that achieves higher exposure. The proposed model allows prediction of brain pharmacodynamics for different species given differing dosing regimens.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP1146699662	Avagacestat		1146699-66-2	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: